跳至主要内容
临床试验/NCT01134640
NCT01134640已完成不适用

A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment

Merck KGaA, Darmstadt, Germany11 个研究点 分布在 1 个国家目标入组 286 人开始时间: 2008年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
286
试验地点
11
主要终点
Safety and toxicity of Erbitux in clinical practice

研究概览

简要总结

A post marketing surveillance, prospective study to collect safety information from 250 subjects with epidermal growth factor receptor (EGFR) expressing, KRAS wild-type metastatic colorectal cancer treated with Erbitux as final evaluable cases.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • EGFR expressing, KRAS wild-type subjects with metastatic colorectal cancer, who are indicated for Erbitux treatment according to the nationally authorized label (in combination with irinotecan, metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy)

排除标准

  • Subjects who are not eligible for Erbitux treatment according to the indication in national label; or with hypersensitivity reactions (grade 3 or 4) to Erbitux

结局指标

主要结局

Safety and toxicity of Erbitux in clinical practice

时间窗: Till 28 days after last dose of Erbitux

To obtain safety information on the use of Erbitux in subjects with metastatic colorectal cancer.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (11)

Loading locations...

相似试验